AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 30049236 — intervention group
Group type: COMPARATOR
Intervention: Animal protein and sugars consumption
Number of subjects: 2413
Study 28915286 — intervention group
Group type: EXPERIMENTAL
Intervention: IVM+BR (Ivermectin 1% cream and Brimonidine 0.33% gel)
Number of subjects: 0
Study 28915286 — intervention group
Group type: EXPERIMENTAL
Intervention: IVM+BR/12 weeks subgroup
Number of subjects: 0
Study 28915286 — intervention group
Group type: EXPERIMENTAL
Intervention: IVM+BR/8 weeks subgroup
Number of subjects: 0
Study 28915286 — intervention group
Group type: COMPARATOR
Intervention: Vehicle group
Number of subjects: 0
Study 28915286 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 0
Study 25324277 — intervention group
Group type: EXPERIMENTAL
Intervention: Four-needle group (LI4, LI11, LI10, TE5)
Number of subjects: 42
Study 25324277 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-needle group (verum at LI4, LI11 and mock at LI10, TE5)
Number of subjects: 42
Study 25324277 — intervention group
Group type: COMPARATOR
Intervention: Mock acupuncture group (LI4, LI11, LI10, TE5)
Number of subjects: 42
Study 23663749 — intervention group
Group type: EXPERIMENTAL
Intervention: Advancing Recovery Framework (payer and treatment organization changes)
Number of subjects: 175
Study 23663749 — intervention group
Group type: COMPARATOR
Intervention: Treatment organization changes alone
Number of subjects: 175
Study 21284066 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 203
Study 21284066 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 203
Study 19920051 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous-flow left ventricular assist device
Number of subjects: 200
Study 19920051 — intervention group
Group type: COMPARATOR
Intervention: Pulsatile-flow left ventricular assist device
Number of subjects: 200
Study 19920051 — intervention group
Group type: EXPERIMENTAL
Intervention: Both devices
Number of subjects: 200
Study 17009635 — intervention group
Group type: EXPERIMENTAL
Intervention: Endometrial cancer group (EC)
Number of subjects: 181
Study 17009635 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 181
Study 15656523 — intervention group
Group type: COMPARATOR
Intervention: Routine group (standard root canal therapy procedures)
Number of subjects: 0
Study 15656523 — intervention group
Group type: EXPERIMENTAL
Intervention: Medicament group (dexamethasone tablets after instrumentation)
Number of subjects: 0
Study 15656523 — intervention group
Group type: EXPERIMENTAL
Intervention: Drainage group (root canals prepared and left open for 2-3 days)
Number of subjects: 0
Study 11134469 — intervention group
Group type: EXPERIMENTAL
Intervention: Zidovudine (ZDV) 300 mg twice daily from 36 weeks' gestation until labor, then every 3 hours until delivery
Number of subjects: 395
Study 11134469 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 395
Study 9138438 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 0
Study 9138438 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol
Number of subjects: 0
Study 7899000 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants completed trials in front of an audience (treatment)
Number of subjects: 60
Study 7899000 — intervention group
Group type: COMPARATOR
Intervention: Participants completed trials alone (control)
Number of subjects: 60
Study 3116443 — intervention group
Group type: EXPERIMENTAL
Intervention: OKT3 (prophylactic use for 1 month)
Number of subjects: 0
Study 3116443 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of azathioprine and OKT3
Number of subjects: 0
Study 3116443 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment (control group)
Number of subjects: 0
Study 2370758 — intervention group
Group type: EXPERIMENTAL
Intervention: Reaferon i.m. administration started on jaundice day 1-5 and lasted for 10-11 days
Number of subjects: 412
Study 2370758 — intervention group
Group type: EXPERIMENTAL
Intervention: Reaferon in delta infection
Number of subjects: 412
Study 2370758 — intervention group
Group type: EXPERIMENTAL
Intervention: Reaferon in fulminant hepatitis
Number of subjects: 412
Study 31747093 — intervention group
Group type: EXPERIMENTAL
Intervention: Unpasteurised maternal milk (MM) intake (mL/kg/d)
Number of subjects: 90
Study 31747093 — intervention group
Group type: EXPERIMENTAL
Intervention: Unpasteurised maternal milk (MM) intake (≥80%)
Number of subjects: 90
Study 31747093 — intervention group
Group type: COMPARATOR
Intervention: Pasteurised donor milk (DM) intake
Number of subjects: 90
Study 31747093 — intervention group
Group type: EXPERIMENTAL
Intervention: Unpasteurised maternal milk (MM) intake
Number of subjects: 90
Study 30739837 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent chemoradiotherapy (CCRT) with weekly cisplatin regimen
Number of subjects: 230
Study 30739837 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy (RT) alone
Number of subjects: 230
Study 28641165 — intervention group
Group type: EXPERIMENTAL
Intervention: Common clinical definition of seizure clusters (≥3 seizures in a day)
Number of subjects: 0
Study 28641165 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel statistical definitions of seizure clusters (≥3 seizures in a day based on statistical exceedance of expected seizure rate)
Number of subjects: 0
Study 25866383 — intervention group
Group type: EXPERIMENTAL
Intervention: MARKIT model for clinical trials management
Number of subjects: 0
Study 23525425 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic TIMI risk score for STEMI
Number of subjects: 0
Study 21518585 — intervention group
Group type: EXPERIMENTAL
Intervention: TIVOLI biodegradable-polymer-based sirolimus-eluting stent
Number of subjects: 324
Study 21518585 — intervention group
Group type: COMPARATOR
Intervention: ENDEAVOR zotarolimus-eluting stent
Number of subjects: 324
Study 18991147 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose doxycycline in a hydrogel
Number of subjects: 49
Study 18991147 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49
Study 16792559 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-methylpyrazole (4-MP) treatment before ethanol consumption
Number of subjects: 32
Study 16792559 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment before ethanol ingestion
Number of subjects: 32
Study 28933336 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxycodone once-daily (OOD) 10 mg (oxycodone HCL 10-mg PR tablets XL)
Number of subjects: 36
Study 28933336 — intervention group
Group type: COMPARATOR
Intervention: Oxycodone twice-daily (OTD) 5 mg (oxygens 5-mg tablets)
Number of subjects: 36
Study 11868856 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma Alpha‐2‐M levels in type 2 diabetic subjects with microalbuminuria
Number of subjects: 100
Study 11868856 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma Alpha‐2‐M levels
Number of subjects: 100
Study 9562231 — intervention group
Group type: EXPERIMENTAL
Intervention: Aminoglycosides (specifically gentamicin)
Number of subjects: 0
Study 9562231 — intervention group
Group type: COMPARATOR
Intervention: Cephalosporins
Number of subjects: 0
Study 9562231 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined administration of cephalosporins and aminoglycosides
Number of subjects: 0
Study 9562231 — intervention group
Group type: EXPERIMENTAL
Intervention: Aminoglycosides
Number of subjects: 0
Study 7930234 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide (80 ppm)
Number of subjects: 16
Study 7930234 — intervention group
Group type: COMPARATOR
Intervention: Nitroprusside (maximally tolerated dose)
Number of subjects: 16
Study 7930234 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide
Number of subjects: 16
Study 2465447 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxazosin
Number of subjects: 40
Study 2465447 — intervention group
Group type: COMPARATOR
Intervention: Atenolol
Number of subjects: 40
Study 29386313 — intervention group
Group type: EXPERIMENTAL
Intervention: Regorafenib 160 mg orally once daily for the first 21 days of each 28-day cycle
Number of subjects: 0
Study 29386313 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 27113960 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus (EVR)
Number of subjects: 70
Study 27113960 — intervention group
Group type: COMPARATOR
Intervention: Calcineurin inhibitor (CNI)
Number of subjects: 70
Study 27113960 — intervention group
Group type: EXPERIMENTAL
Intervention: Difference in IMR change between EVR and CNI
Number of subjects: 70
Study 25276763 — intervention group
Group type: EXPERIMENTAL
Intervention: IUD ML CU 375
Number of subjects: 48
Study 25276763 — intervention group
Group type: COMPARATOR
Intervention: IUD Copper T 380A
Number of subjects: 48
Study 23423269 — intervention group
Group type: COMPARATOR
Intervention: Continuous corticosteroid therapy (CCS)
Number of subjects: 386
Study 23423269 — intervention group
Group type: EXPERIMENTAL
Intervention: Early corticosteroid withdrawal (CSWD)
Number of subjects: 386
Study 23423269 — intervention group
Group type: EXPERIMENTAL
Intervention: BCAR+BL
Number of subjects: 386
Study 20607434 — intervention group
Group type: EXPERIMENTAL
Intervention: Promotora-led educational intervention
Number of subjects: 0
Study 17728331 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept (ETN) added to Methotrexate (MTX)
Number of subjects: 227
Study 17728331 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX) added to Etanercept (ETN)
Number of subjects: 227
Study 17728331 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (ETN + MTX)
Number of subjects: 227
Study 17728331 — intervention group
Group type: COMPARATOR
Intervention: Control group (previously receiving MTX or ETN monotherapy)
Number of subjects: 227
Study 16887889 — intervention group
Group type: EXPERIMENTAL
Intervention: Concept mapping intervention
Number of subjects: 84
Study 16887889 — intervention group
Group type: EXPERIMENTAL
Intervention: Professionals' focus on positive aspects of medication
Number of subjects: 84
Study 12746623 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-monitoring of blood glucose (SMBG) in non-insulin-treated type 2 DM
Number of subjects: 0
Study 12746623 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-monitoring of blood glucose (SMBG) in insulin-treated type 2 DM
Number of subjects: 0
Study 12746623 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured counseling educational programs for SMBG
Number of subjects: 0
Study 11726257 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate Load (ML) - 13-15 repetitions with a moderate load on the chest press exercise, n = 16
Number of subjects: 54
Study 11726257 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination Exercise (CX) - 6-8 repetitions with a heavy load on the chest press exercise immediately followed by 6-8 medicine ball chest passes, n = 12
Number of subjects: 54
Study 11726257 — intervention group
Group type: EXPERIMENTAL
Intervention: Heavy Load (HL) - 6-8 repetitions with a heavy load on the chest press exercise, n = 15
Number of subjects: 54
Study 11726257 — intervention group
Group type: EXPERIMENTAL
Intervention: Medicine Ball (MB) - 13-15 medicine ball chest passes, n = 11
Number of subjects: 54
Study 11726257 — intervention group
Group type: COMPARATOR
Intervention: Control (CT) - Nontraining controls, n = 12
Number of subjects: 54
Study 9222012 — intervention group
Group type: EXPERIMENTAL
Intervention: Fallopian tube epithelial cell co-culture
Number of subjects: 91
Study 9222012 — intervention group
Group type: COMPARATOR
Intervention: Conventional culture medium (Control)
Number of subjects: 91
Study 7659824 — intervention group
Group type: EXPERIMENTAL
Intervention: Drainage withdrawn at 24 hours
Number of subjects: 106
Study 7659824 — intervention group
Group type: EXPERIMENTAL
Intervention: Drainage withdrawn at 72 hours
Number of subjects: 106
Study 7659824 — intervention group
Group type: EXPERIMENTAL
Intervention: Drainage withdrawn at 72 hours with previous vesical reeducation
Number of subjects: 106
Study 2821052 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone (10-mg iv bolus dose followed by an infusion of 30 micrograms/kg . h)
Number of subjects: 10
Study 2821052 — intervention group
Group type: COMPARATOR
Intervention: NaCl (control)
Number of subjects: 10
Study 28081223 — intervention group
Group type: EXPERIMENTAL
Intervention: Jump training (JUMP) - 5-6 sessions per week consisting of 4x10 countermovement jumps and 2x10 hops in a sledge jump system.
Number of subjects: 23
Study 28081223 — intervention group
Group type: COMPARATOR
Intervention: Control group (CTRL) - no jump training.
Number of subjects: 23
Study 25687667 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness training plus standard health education (HE-M)
Number of subjects: 60
Study 25687667 — intervention group
Group type: COMPARATOR
Intervention: Attention-control intervention plus standard health education (HE-AC)
Number of subjects: 60
Study 23355361 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose of ranolazine 500 mg
Number of subjects: 12
Study 23355361 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose of ranolazine 1,000 mg
Number of subjects: 12
Study 23355361 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose of ranolazine 1,500 mg
Number of subjects: 12
Study 23355361 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple doses of ranolazine 500 mg twice daily for 7 days
Number of subjects: 12
Study 21289042 — intervention group
Group type: EXPERIMENTAL
Intervention: Inactivated influenza vaccine
Number of subjects: 439
Study 21289042 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 439
Study 19422663 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemoimmunotherapy (combination of immunotherapy and chemotherapy); specific dosages and duration not available.
Number of subjects: 0
Study 17350383 — intervention group
Group type: EXPERIMENTAL
Intervention: Anger provocation interview
Number of subjects: 14
Study 17350383 — intervention group
Group type: COMPARATOR
Intervention: Neutral interview
Number of subjects: 14
Study 15478751 — intervention group
Group type: EXPERIMENTAL
Intervention: Ecological approach to data selection (contrast class account)
Number of subjects: 50
Study 15478751 — intervention group
Group type: COMPARATOR
Intervention: Heuristic approach to data selection
Number of subjects: 50
Study 11911409 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytosine arabinoside (ara-C) dose escalation to 15 and 20 mg/m2/d for 1-10 days
Number of subjects: 119
Study 9840848 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine at 4 mL/hour
Number of subjects: 128
Study 9840848 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine at 6 mL/hour
Number of subjects: 128
Study 9840848 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine at 8 mL/hour
Number of subjects: 128
Study 9840848 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine at 10 mL/hour
Number of subjects: 128
Study 9840848 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 128
Study 8030688 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous combined estradiol and norethindrone acetate (Kliogest)
Number of subjects: 113
Study 8030688 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential estradiol and norethindrone acetate (Trisequens)
Number of subjects: 113
Study 8030688 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 113
Study 2913773 — intervention group
Group type: EXPERIMENTAL
Intervention: Prazosin
Number of subjects: 19
Study 2913773 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 19
Study 2913773 — intervention group
Group type: COMPARATOR
Intervention: Control (Placebo)
Number of subjects: 19
Study 1176289 — intervention group
Group type: EXPERIMENTAL
Intervention: Kallikrein (a kinin-liberating proteinase) administered parenterally and orally over a period of seven weeks.
Number of subjects: 30
Study 1176289 — intervention group
Group type: EXPERIMENTAL
Intervention: Parenteral application of kallikrein.
Number of subjects: 30
Study 1176289 — intervention group
Group type: EXPERIMENTAL
Intervention: Kallikrein treatment.
Number of subjects: 30
Study 29790405 — intervention group
Group type: EXPERIMENTAL
Intervention: Health education intervention during 6-month therapy
Number of subjects: 200
Study 29790405 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 200
Study 27973678 — intervention group
Group type: EXPERIMENTAL
Intervention: Xbox KinectTM training for 20 sessions
Number of subjects: 20
Study 27973678 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy (control group)
Number of subjects: 20
Study 27973678 — intervention group
Group type: EXPERIMENTAL
Intervention: Xbox KinectTM training
Number of subjects: 20
Study 25414475 — intervention group
Group type: EXPERIMENTAL
Intervention: Benztropine (2 mg intramuscular)
Number of subjects: 30
Study 25414475 — intervention group
Group type: COMPARATOR
Intervention: Placebo (normal saline)
Number of subjects: 30
Study 23911117 — intervention group
Group type: EXPERIMENTAL
Intervention: Visually demanding near work under four different trial-lens conditions
Number of subjects: 66
Study 21903010 — intervention group
Group type: EXPERIMENTAL
Intervention: Body-weight-supported (BWS) ambulation on a fixed track (TRK)
Number of subjects: 35
Study 21903010 — intervention group
Group type: EXPERIMENTAL
Intervention: Body-weight-supported (BWS) ambulation on a treadmill (TM)
Number of subjects: 35
Study 21903010 — intervention group
Group type: COMPARATOR
Intervention: Comprehensive physical therapy (PT)
Number of subjects: 35
Study 19549678 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrial overdrive pacing (AOP)
Number of subjects: 175
Study 19549678 — intervention group
Group type: COMPARATOR
Intervention: Continuous positive airway pressure (CPAP)
Number of subjects: 175
Study 16702572 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycopyrrolate (administered to induce acute xerostomia in 10 men)
Number of subjects: 20
Study 16702572 — intervention group
Group type: COMPARATOR
Intervention: Saline (administered to 10 men who served as controls)
Number of subjects: 20
Study 14751424 — intervention group
Group type: EXPERIMENTAL
Intervention: risperidone 1‐12 mg
Number of subjects: 41
Study 14751424 — intervention group
Group type: COMPARATOR
Intervention: haloperidol 2‐20 mg
Number of subjects: 41
Study 11315533 — intervention group
Group type: EXPERIMENTAL
Intervention: CBT approach
Number of subjects: 78
Study 11315533 — intervention group
Group type: COMPARATOR
Intervention: Conjoint family therapy and eclectic approach
Number of subjects: 78
Study 11315533 — intervention group
Group type: EXPERIMENTAL
Intervention: Naturalistic follow-up design
Number of subjects: 78
Study 9452539 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoral lidocaine patches
Number of subjects: 0
Study 9452539 — intervention group
Group type: COMPARATOR
Intervention: Matching placebo patches
Number of subjects: 0
Study 8950444 — intervention group
Group type: EXPERIMENTAL
Intervention: Simple ligation
Number of subjects: 200
Study 8950444 — intervention group
Group type: COMPARATOR
Intervention: Ligation and inversion of the appendix stump
Number of subjects: 200
Study 2124243 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon gamma (100 micrograms per subcutaneous injection, daily for the first 2 weeks, then 3 times per week)
Number of subjects: 80
Study 2124243 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 2124243 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon gamma (100 micrograms per subcutaneous injection)
Number of subjects: 80
Study 6996784 — intervention group
Group type: EXPERIMENTAL
Intervention: Pseudoephedrine
Number of subjects: 466
Study 6996784 — intervention group
Group type: EXPERIMENTAL
Intervention: Pseudoephedrine and triprolidine combination
Number of subjects: 466
Study 6996784 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 466
Study 31791405 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive tablet-based education intervention
Number of subjects: 1200
Study 31791405 — intervention group
Group type: COMPARATOR
Intervention: Control with no intervention
Number of subjects: 1200
Study 27874185 — intervention group
Group type: EXPERIMENTAL
Intervention: Delirium-friendly preprinted postoperative orders (PPOs)
Number of subjects: 283
Study 27874185 — intervention group
Group type: COMPARATOR
Intervention: Routine postoperative orders
Number of subjects: 283
Study 27874185 — intervention group
Group type: EXPERIMENTAL
Intervention: Delirium-friendly PPOs
Number of subjects: 283
Study 24921611 — intervention group
Group type: EXPERIMENTAL
Intervention: Basketball Plyometric Training (BPT)
Number of subjects: 36
Study 24921611 — intervention group
Group type: COMPARATOR
Intervention: Basketball Technique Training (BTT)
Number of subjects: 36
Study 24628966 — intervention group
Group type: EXPERIMENTAL
Intervention: Dark chocolate
Number of subjects: 60
Study 24628966 — intervention group
Group type: COMPARATOR
Intervention: White chocolate
Number of subjects: 60
Study 22443058 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron supplementation (8 mg daily of ferric pyrophosphate and ferrous fumarate)
Number of subjects: 74
Study 20491957 — intervention group
Group type: EXPERIMENTAL
Intervention: PEGLip‐formulated FVIIa
Number of subjects: 0
Study 20491957 — intervention group
Group type: COMPARATOR
Intervention: Standard FVIIa
Number of subjects: 0
Study 20491957 — intervention group
Group type: EXPERIMENTAL
Intervention: PEGLip‐formulated FVIIa and Standard FVIIa
Number of subjects: 0
Study 18713232 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium dobesilate 1 g twice per day
Number of subjects: 0
Study 18713232 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 15824342 — intervention group
Group type: EXPERIMENTAL
Intervention: High-resolution T2 reversed (T2R) MRI
Number of subjects: 15
Study 15824342 — intervention group
Group type: COMPARATOR
Intervention: Normal volunteers (control group)
Number of subjects: 15
Study 15824342 — intervention group
Group type: COMPARATOR
Intervention: Disease controls (stroke or tumor subjects)
Number of subjects: 15
Study 11840097 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mL 0.25% bupivacaine
Number of subjects: 44
Study 11840097 — intervention group
Group type: COMPARATOR
Intervention: 20 mL 0.9% saline
Number of subjects: 44
Study 11840097 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 44
Study 10803112 — intervention group
Group type: EXPERIMENTAL
Intervention: Dyract (DY) with conventional polymerization (CP)
Number of subjects: 20